Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)

Afatinib is an ErbB family blocker approved for the treatment of epidermal growth factor receptor mutation‐positive nonsmall‐cell lung cancer. A pivotal trial demonstrated significant clinical benefits with manageable toxicity of afatinib as a second‐line treatment option in squamous cell carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung Hyeun, Park, Cheol‐Kyu, Lee, Sung Yong, Choi, Chang‐Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046099/
https://www.ncbi.nlm.nih.gov/pubmed/33586312
http://dx.doi.org/10.1111/1759-7714.13880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046099/
https://www.ncbi.nlm.nih.gov/pubmed/33586312
http://dx.doi.org/10.1111/1759-7714.13880

Ejemplares similares